Evotec
York Rudhard has extensive work experience in the scientific field. York began their career in 2001 as a Postdoctoral Fellow at University College London, where they worked until 2003. From there, they joined the Center for Molecular Neurobiology Hamburg as a Postdoctoral Fellow, where they worked until 2006. York then joined Evotec as a Research Scientist, and later progressed to the role of Senior Research Scientist from 2011 to 2015. In 2015, York Rudhard became a Principal Scientist at Evotec. Currently, they hold the position of VP, Scientific Director Translational Studies at Evotec.
York Rudhard earned a Doctor of Philosophy (Ph.D.) degree in Molecular Pharmacology from UCL in 2001. Prior to that, they obtained a Master's Degree in Biology from Heidelberg University in 1996. There is no information provided about York Rudhard's education prior to their time at Heidelberg University.
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.